Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Increased one-year risk of symptomatic venous thromboembolism following total hip replacement: a nationwide cohort study.

Pedersen AB, Johnsen SP, Sørensen HT.

J Bone Joint Surg Br. 2012 Dec;94(12):1598-603. doi: 10.1302/0301-620X.94B12.29358.

PMID:
23188898
2.

Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes.

Penning-van Beest FJ, Overbeek JA, Meijer WM, Woodruff K, Jackson J, van der Vis H, van der Linden P, Herings RM.

Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):972-8. doi: 10.1002/pds.2187. Epub 2011 Jul 11.

PMID:
21748826
3.

The risk of venous thromboembolism, myocardial infarction, stroke, major bleeding and death in patients undergoing total hip and knee replacement: a 15-year retrospective cohort study of routine clinical practice.

Pedersen AB, Mehnert F, Sorensen HT, Emmeluth C, Overgaard S, Johnsen SP.

Bone Joint J. 2014 Apr;96-B(4):479-85. doi: 10.1302/0301-620X.96B4.33209.

PMID:
24692614
4.

Risk factors and distribution of symptomatic venous thromboembolism in total hip and knee replacements: prospective study.

Markovic-Denic L, Zivkovic K, Lesic A, Bumbasirevic V, Dubljanin-Raspopovic E, Bumbasirevic M.

Int Orthop. 2012 Jun;36(6):1299-305. doi: 10.1007/s00264-011-1466-5. Epub 2012 Jan 4.

5.

Prolonged outpatient vitamin K antagonist use and risk of venous thromboembolism in patients undergoing total hip or knee replacement.

Lalmohamed A, Vestergaard P, Jansen PA, Grove EL, de Boer A, Leufkens HG, van Staa TP, de Vries F.

J Thromb Haemost. 2013 Apr;11(4):642-50. doi: 10.1111/jth.12158.

6.

Short- and long-term mortality following primary total hip replacement for osteoarthritis: a Danish nationwide epidemiological study.

Pedersen AB, Baron JA, Overgaard S, Johnsen SP.

J Bone Joint Surg Br. 2011 Feb;93(2):172-7. doi: 10.1302/0301-620X.93B2.25629.

PMID:
21282754
7.

Risk factors for venous thromboembolism in patients undergoing total hip replacement and receiving routine thromboprophylaxis.

Pedersen AB, Sorensen HT, Mehnert F, Overgaard S, Johnsen SP.

J Bone Joint Surg Am. 2010 Sep 15;92(12):2156-64. doi: 10.2106/JBJS.I.00882.

PMID:
20844157
8.

Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.

Vekeman F, LaMori JC, Laliberté F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

J Med Econ. 2011;14(3):324-34. doi: 10.3111/13696998.2011.578698. Epub 2011 Apr 20.

PMID:
21506632
9.

Stress-induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty: analysis from the RECORD trials.

Cohn DM, Hermanides J, DeVries JH, Kamphuisen PW, Kuhls S, Homering M, Hoekstra JB, Lensing AW, Büller HR.

Thromb Haemost. 2012 Feb;107(2):225-31. doi: 10.1160/TH11-07-0447. Epub 2011 Dec 21.

PMID:
22187097
10.

Effectiveness and safety of different duration of thromboprophylaxis in 16,865 hip replacement patients--a real-word, prospective observational study.

Pedersen AB, Sorensen HT, Mehnert F, Johnsen SP, Overgaard S.

Thromb Res. 2015 Feb;135(2):322-8. doi: 10.1016/j.thromres.2014.11.029. Epub 2014 Dec 3.

PMID:
25511580
11.

Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study.

Mismetti P, Samama CM, Rosencher N, Vielpeau C, Nguyen P, Deygas B, Presles E, Laporte S; PROPICE Study Group.

Thromb Haemost. 2012 Jun;107(6):1151-60. doi: 10.1160/TH11-09-0640. Epub 2012 Apr 4.

PMID:
22476471
12.

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.

Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.

Pharmacoeconomics. 2012 Feb 1;30(2):87-101. doi: 10.2165/11599370-000000000-00000.

PMID:
22187932
13.

Clinical venous thromboembolism following joint surgery: effect of extended thromboprophylaxis on its annual frequency and postoperative pattern over 22 years.

Dahl OE, Gudmundsen TE, Pripp AH, Aanesen JJ.

Clin Appl Thromb Hemost. 2014 Mar;20(2):117-23. doi: 10.1177/1076029613499820. Epub 2013 Oct 10.

PMID:
24113492
14.

Impact of thromboprophylaxis guidelines on clinical outcomes following total hip and total knee replacement.

Selby R, Borah BJ, McDonald HP, Henk HJ, Crowther M, Wells PS.

Thromb Res. 2012 Aug;130(2):166-72. doi: 10.1016/j.thromres.2012.01.013. Epub 2012 Feb 23.

PMID:
22365491
15.

Timing of acute myocardial infarction in patients undergoing total hip or knee replacement: a nationwide cohort study.

Lalmohamed A, Vestergaard P, Klop C, Grove EL, de Boer A, Leufkens HG, van Staa TP, de Vries F.

Arch Intern Med. 2012 Sep 10;172(16):1229-35. doi: 10.1001/archinternmed.2012.2713.

PMID:
22826107
16.

Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.

Colwell CW Jr, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, Neubauer J, McElhattan JL, Peters GR, Francis CW.

J Thromb Haemost. 2003 Oct;1(10):2119-30.

17.

Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006.

Cronin-Fenton DP, Søndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, Baron JA, Sørensen HT.

Br J Cancer. 2010 Sep 28;103(7):947-53. doi: 10.1038/sj.bjc.6605883. Epub 2010 Sep 14.

18.

Symptomatic venous thromboembolism following a hip fracture.

McNamara I, Sharma A, Prevost T, Parker M.

Acta Orthop. 2009 Dec;80(6):687-92. doi: 10.3109/17453670903448273.

19.
20.

Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study.

Samama CM, Ravaud P, Parent F, Barré J, Mertl P, Mismetti P.

J Thromb Haemost. 2007 Dec;5(12):2360-7. Epub 2007 Oct 1.

Supplemental Content

Support Center